Toyoki Mori

Characterization of a novel aquaretic agent, OPC‐31260, as an orally effective, nonpeptide vasopressin V₂ receptor antagonist

Yoshitaka Yamamura, Hidenori Ogawa, Hiroshi Yamashita et al. · British Journal of Pharmacology · 1992 · 346 citations · Full text

OPC-41061, a Highly Potent Human Vasopressin V2-Receptor Antagonist: Pharmacological Profile and Aquaretic Effect by Single and Multiple Oral Dosing in Rats

Yoshitaka Yamamura, Shigeki Nakamura, S. Itoh et al. · Journal of Pharmacology and Experimental Therapeutics · 1998 · 327 citations · Full text

OPC-21268, an Orally Effective, Nonpeptide Vasopressin V1 Receptor Antagonist

Yoshitaka Yamamura, Hidenori Ogawa, Tomihiko Chihara et al. · Science · 1991 · 272 citations

Hypertension, Heart Failure, Arginine Vasopressin +14

The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions

Akito Tanoue, Shuji Ito, Kenji Honda et al. · Journal of Clinical Investigation · 2004 · 222 citations · Full text

Pituitary Cells, Gastrointestinal Peptide Hormone, Adrenal Gland +17

Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism

Ayako Hashimoto, Goro Miyakoda, Yoshimi Hirose et al. · Atherosclerosis · 2006 · 211 citations

Inflammation, Molecular Pharmacology, Molecular Physiology +14